

TRIMEDYNE REPORTS FINANCIAL RESULTS
FOR THE QUARTER ENDED DECEMBER 31, 2005

FOR IMMEDIATE RELEASE

CONTACT: Jeff Rudner
(949) 951-3800, Ext. 285
jrudner@trimedyne.com

February 15, 2006 - Trimedyne, Inc., Irvine, CA (OTCBB "TMED"), today reported in revenues of \$1,785,000 for the quarter ended December 31, 2005, a 3% decrease from revenues of \$ 1,839,000 for the same quarter of the prior year.

Net profit was \$14,000 or \$0.00 per share for the current quarter, compared to a net profit of \$173,000 or \$0.01 per share in the prior year quarter. R & D costs in the current quarter increased 9% to \$145,000, versus \$133,000 for the previous year quarter.

Glenn D. Yeik, President of Trimedyne, said, "Sales of lasers increased in the current quarter, while sales of disposables decreased. However, lasers in this quarter were sold at lower average prices, due to competition, and lasers carry lower margins than disposables. As a result, our profit margin declined to 36% of sales from 49% in the prior year quarter, reducing our net profit for the current quarter. Sales of our new, disposable VaporMAX™ fiber are expected to begin to contribute to revenues in the quarter ended June 30, 2006, although such cannot be assured."

Trimedyne manufactures lasers and proprietary fiber optic devices for a variety of minimally invasive surgical procedures, many of which are performed on an outpatient basis at substantially less cost than conventional surgery. For product, financial and other information, visit Trimedyne's website, <http://www.trimedyne.com>.

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act:

Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent report on Form 10-KSB and subsequently filed SEC reports. There is no assurance any new products can be cleared for sale by the FDA or successfully commercialized or any forward-looking statements will prove accurate, as actual results and future events could differ materially from those presently anticipated.

* * * *

TRIMEDYNE, INC.
CONSOLIDATED BALANCE SHEET
(UNAUDITED)

ASSETS

	December 31, 2005
Current assets:	
Cash and cash equivalents	\$ 1,699,000
Trade accounts receivable, net of allowance for doubtful accounts of \$86,000	718,000
Inventories	1,972,000
Other	176,000
Total current assets	4,565,000
Property and equipment, net	337,000
Goodwill	544,000
Other assets	95,000
	\$ 5,541,000

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:	
Accounts payable	\$ 312,000
Accrued expenses	340,000
Deferred revenue	40,000
Accrued warranty	58,000
Income tax payable	8,000
Notes payable and current portion of long-term debt	12,000
Total current liabilities	770,000
Senior convertible secured notes due to officer	200,000
Accrued interest due officer	93,000
Long-term debt, net of current portion	4,000
Total liabilities	1,067,000
Commitments and Contingencies	
Stockholders' equity:	
Preferred stock - \$0.01 par value, 1,000,000 shares authorized, none issued and outstanding	
Common stock - \$0.01 par value; 30,000,000 shares authorized, 14,704,540 shares issued, 14,602,931 shares outstanding	148,000
Capital in excess of par value	47,945,000
Accumulated deficit	(42,906,000)
Treasury stock, at cost (101,609 shares)	5,187,000 (713,000)
Total stockholders' equity	4,474,000
	\$ 5,541,000

TRIMEDYNE, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

	Three Months Ended December 31,	
	2005	2004
Net revenues	\$ 1,785,000	\$ 1,839,000
Cost of revenues	1,148,000	936,000
Gross profit	637,000	903,000
Operating expenses:		
Selling, general and administrative	580,000	623,000
Research and development	145,000	133,000
Total operating expenses	725,000	756,000
Income (loss) from operations	(88,000)	147,000
Other income, net	103,000	26,000
Income before income taxes	15,000	173,000
Provision for income taxes	1,000	--
Net (loss) income	\$ 14,000	\$ 173,000
Net (loss) income per share:		
Basic	\$ 0.00	\$ 0.01
Diluted	\$ 0.00	\$ 0.01
Weighted average number of shares outstanding:		
Basic	14,704,540	14,704,540
Diluted	15,445,735	15,388,385